- Simtra BioPharma Solutions announces $14 million investment to expand ADC manufacturing.
- New capabilities at the Halle/Westfalen site to be operational by late 2025.
Simtra BioPharma Solutions, a contract development and manufacturing organisation (CDMO) specialising in sterile injectables, has announced a $14 million investment aimed at expanding its clinical-scale conjugation and purification services for Antibody-Drug Conjugates (ADCs). The investment is part of Simtra’s broader strategy to offer end-to-end services, from development to clinical and commercial fill/finish, and will be completed by late 2025.
The expanded clinical suite, located at Simtra’s Halle/Westfalen site in Germany, will provide key ADC development capabilities, including conjugation mixing, single-use tangential flow filtration, and buffer exchange. The site, already known for its expertise in oncology and ADCs, operates under SafeBridge classification and handles high-potency Category 4 drugs.
CEO Franco Negron noted the strategic value of the expansion, stating, “This investment will further strengthen Simtra’s leadership in ADC manufacturing, a growing sector, by extending our capabilities in support of our customers and partners in the value chain.”
In addition, Lidia Serina, Head of Development Services at Simtra, emphasised the advantages for customers, highlighting that the company now offers a complete solution, from early development through to commercial production. This, she said, allows for more flexibility, reduced risk, and shorter timelines, ultimately benefiting customers.
Overview of outsourcing trends 
